In briefBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7239.890/b (Published 01 April 2000) Cite this as: BMJ 2000;320:890
Troglitazone (Rezulin) taken off US market: The US Food and Drug Administration has requested that troglitazone (Rezulin), an antidiabetic drug manufactured by Parke-Davis, should be withdrawn from the market. Since its introduction in March 1997, troglitazone has been linked to 90 cases of hepatic failure, resulting in 63n …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial